Top Orphan Drugs Rare Disease Therapies 2021

Global Orphan Drugs Rare Disease Therapy Market Opportunity Estimated At USD 350 Billion By 2021 Says Kuick Research

 

Global Orphan Drugs Market & Clinical Trials Insight Report 2028 Highlights:

 

  • Clinical Insight On More Than 600 Marketed Orphan Drugs
  • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials
  • Orphan Designated Drug Clinical Status by Indication & Country
  • Global Market Opportunity More Than USD 350 Billion
  • Market Exclusivity & Patent Protection Criteria for Orphan Drugs
  • Global & Regional Orphan Drug Market Sales Opportunity
  • Orphan Drug Reimbursement Policy
  • Orphan Clinical Pipeline Overview Company, Drug Class, Formulation, Indication, Region, Priority Status, Patient Segment, Phase

 

Download Report Sample:

 

https://www.kuickresearch.com/ccformF.php?t=1643976472

 

Orphan drugs refer to the pharmaceuticals which are used for the diagnosis, prevention, and treatment of rare medical disorders. Rare diseases are a health condition which generally affects small number of people compared with other prevalent diseases in general population. It is estimated that globally around 6000-8000 rare diseases exist with new rare diseases being reported in medical literature regularly. As rare diseases have low prevalence and individually rare, collectively they affect around 6-8% of the population. These diseases include genetic disorders, rare cancers, infectious topical diseases, and degenerative diseases. Around 80% of the rare diseases are genetic in nature and therefore mainly affects children.

 

The last few years have seen rapid influx in approval of orphan drugs which is mainly attributed to the restless efforts by scientists and rising awareness among population. Several orphan drugs including Imbruvica, Revlimid, Trikafta, Hemlibra, and others have shown robust response in the market. The top selling orphan drugs in the market are mentioned in table below.

 

Presently, oncology orphan drugs occupy the majority of share in the market. Almost 200 rare cancers have been identified which all together represent 22% of all cancer incidences. It has been suggested that except for 5 major tumors including breast, lung, colorectal, prostate, and bladder cancers, all others are classified as rare. Moreover, the advancements in the science and technology and better understanding of cancer has allowed further segmentation of cancer types in smaller subgroups.

 

Key Orphan Drug Sales 2021:

 

Drug

Company

FDA Approval

Indication

2021 Sales

Keytruda

Merck

2014

melanoma, NSCLC, HNSCC, classical HL, primary mediastinal large B-cell lymphoma, urothelial carcinoma, CRC, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and TNBC.

US$ 17.18 Billion

Revlimid

Bristo Myers Squibb

2005

Multiple myeloma, Follicular Lymphoma, myelodysplastic syndromes, mantle cell lymphoma, marginal zonal lymphoma

US$ 12.8 Billion

Opdivo

Bristo Myers Squibb

2014

NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, HNSCC, urothelial carcinoma, CRC, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer.

US$ 7.52 Billion

Trikafta

Vertex Pharmaceutical

2019

Cystic Fibrosis

US$ 5.69 Billion

Imbruvica

AbbVie

2015

Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma

US$ 5.4 Billion

Hemlibra

Genentech

2017

Hemophilia A

US$ 2.35 Billion

Lynparza

AstraZeneca

2014

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer

US$ 2 Billion

Vyndaqel

Pfizer

2019

Cardiomyopathy of Transthyretin-Mediated Amyloidosis

US$ 2 Billion

Darzalex

Janssen Biotech

2015

Multiple Myeloma

US$ 1.64 Billion

Soliris

Alexion Pharmaceuticals

 

2007

Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome, Myasthenia Gravis

US$ 1 Billion

Venclexta

Abbvie

2016

Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia

US$ 934 Million

Jakafi

Incyte Corporation

2011

Myelofibrosis

US$ 592 Million

 

 

For More Information Related To Report Contact:

 

Neeraj Chawla

Research Head

Kuick Research

neeraj@kuickresearch.com

+919810410366

Back to news